105786-35-4

Basic information

• Product Name: DIEXO-3-AMINO-BICYCLO[2.2.1]HEPTANE-2-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: DIEXO-3-AMINO-BICYCLO[2.2.1]HEPTANE-2-CARBOXYLIC ACID ETHYL ESTER
• CAS NO: 105786-35-4
• Molecular Formula: C₁₀H₁₇NO₂
• Molecular Weight: 183.25
• Mol File: 105786-35-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 254.148°C at 760 mmHg
• Flash Point: 117.609°C
• Appearance: /
• Density: 1.098g/cm³
• Vapor Pressure: 0.018mmHg at 25°C
• Refractive Index: 1.505
• CAS DataBase Reference: DIEXO-3-AMINO-BICYCLO[2.2.1]HEPTANE-2-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: DIEXO-3-AMINO-BICYCLO[2.2.1]HEPTANE-2-CARBOXYLIC ACID ETHYL ESTER(105786-35-4)
• EPA Substance Registry System: DIEXO-3-AMINO-BICYCLO[2.2.1]HEPTANE-2-CARBOXYLIC ACID ETHYL ESTER(105786-35-4)

Safety Data

• Hazardous Substances Data: 105786-35-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H17NO2/c1-2-13-10(12)8-6-3-4-7(5-6)9(8)11/h6-9H,2-5,11H2,1H3/t6-,7+,8+,9-/m0/s1

Upstream product

• 7486-95-5 exo-3-azatricyclo<4.2.1.0^2,5>nonan-4-one 
• 498-66-8 norborn-2-ene 
• 179462-36-3 (±)-cis-3-aminobicyclo[2.2.1]heptane-2-carboxylic acid hydrochloride 
• 144-55-8 sodium hydrogencarbonate 
• 95630-75-4 ethyl exo-3-aminobicyclo<2.2.1>heptane-2-exo-carboxylate hydrochloride 
• 498-66-8 norbornene 
• 179462-36-3 rac-3-amino-bicyclo[2.2.1]heptane-2-carboxylic acid hydrochloride 
• 874292-70-3 rac-3-aza-tricyclo[4.2.1.0^2,5]nonan-4-one 
• 95630-75-4 Ethyl 3-endo-Aminobicyclo<2.2.1>heptane-2-endo-carboxylate Hydrochloride 
• 53623-52-2 3-endo-Aminobicyclo<2.2.1>hept-5-ene-2-endo-carboxylic Acid 
• 76198-36-2 3-exo-Aminobicyclo<2.2.1>heptane-2-exo-carboxylic Acid 
• 95630-74-3 Ethyl 3-endo-Aminobicyclo<2.2.1>hept-5-ene-2-endo-carboxylate Hydrochloride 

Downstream Products

• 105786-39-8 exo-3-aminobicyclo<2.2.1>heptane-exo-2-carboxamide 
• 95630-60-7 2-Phenyl-5,8-methano-r-4a,t-5,6,7,t-8,c-8a-hexahydro-4H-3,1-benzoxazine 
• 87768-86-3 2-(4-Tolyl)-5,8-methano-r-4a,t-5,6,7,t-8,c-8a-hexahydro-4H-3,1-benzoxazine 
• 87768-88-5 2-(3-Chlorophenyl)-5,8-methano-r-4a,t-5,6,7,t-8,c-8a-hexahydro-4H-3,1-benzoxazine 
• 87768-87-4 2-(4-Chlorophenyl)-5,8-methano-r-4a,t-5,6,7,t-8,c-8a-hexahydro-4H-3,1-benzoxazine 
• 1071520-41-6 (1S,2R,3S,4R)-3-(4-fluoro-benzylamino)-bicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester 
• 1071520-38-1 (1R,2S,3R,4S)-3-ethoxycarbonyl-bicyclo [2.2.1]hept-2-yl-aminium (S)-α-hydroxyphenylacetate 
• 1071517-82-2 (1S,2R,3S,4R)-3-(4-fluoro-benzyl)-6-hydroxy-5-(7-iodo-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl)-3-aza-tricyclo[6.2.1.0(2,7)]undec-5-en-4-one 
• 1071517-39-9 N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.0(2,7)]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide 
• 1071520-44-9 (1S,2R,3S,4R)-3-{(4-fluorobenzyl)-[2-(7-methanesulfonylamino-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl)acetyl]amino}bicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester 
• 1071519-59-9 N-{3-[(1R,2S,7R,8S)-3-(4-fluorobenzyl)-6-hydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide L-arginine salt 
• 1071519-62-4 N-{3-[(1R,2S,7R,8S)-3-(4-fluorobenzyl)-6-hydroxy-4-oxo-3-azatricyclo[6.2.1.02,7]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide L-lysine salt 
• 1071519-66-8 N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.0(2,7)]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide sodium salt 
• 1071519-68-0 N-{3-[(1R,2S,7R,8S)-3-(4-fluoro-benzyl)-6-hydroxy-4-oxo-3-aza-tricyclo[6.2.1.0(2,7)]undec-5-en-5-yl]-1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-7-yl}methanesulfonamide potassium salt 

Relevant articles and documents

[1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID

The present invention describes [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutically acceptable salts thereof, which are useful in lowering serum uric acid in a patient in need thereof comprising administering to the patient a therapeutically or

[1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS

The invention is directed to [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS

The invention is directed to 5,6-dihydro-lH-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.